Corporate Profile

Forward Pharma is a NASDAQ traded Danish biopharmaceutical company that since 2005 has been developing FP187, a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications. The Company owns a significant intellectual property (IP) portfolio related to DMF formulations. We granted to Biogen an irrevocable license to all of our IP through the recent Settlement and License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion on February 9, 2017. We have opportunities to receive royalties from Biogen on sales of Tecfidera® or other DMF products for MS, dependent on, among other things, the U.S. interference outcome, Hart-Scott-Rodino (HSR) antitrust clearance and the ‘355 opposition outcome in Europe.

Forward Pharma A/S was founded in 2005 and is headquartered in Copenhagen, Denmark, in the heart of Medicon Valley. Since 2007 we have also operated out of a subsidiary, Forward Pharma GmbH, in Leipzig, Germany, and since August 2014 out of a subsidiary in the United States, Forward Pharma USA, LLC.

Most Recent Presentation
Download Documentation Credit Suisse Healthcare Conference

Stock Information
FWP (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Financial Status IndicatorC
Change (%) Stock is Up 0.77 (0.00%)
Data as of 03/23/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Stock chart for: FWP.OQ.  Currently trading at $27.82 with a 52 week high of $32.70 and a 52 week low of $14.89.

Recent NewsMore >>
03/01/17Forward Pharma Appoints Claus Bo Svendsen as Chief Executive Officer and Plans to Reorganize to Reduce Burn Rate Following the Settlement and License Agreement with Biogen
COPENHAGEN, Denmark, March 01, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or the “Company”) today announced that its Board of Directors has appointed Claus Bo Svendsen, M.D., Ph.D. as Chief Executive Officer, effective March 1, 2017. He previously held the position of Executive Vice President at the Company. Dr. Svendsen succeeds Peder M. Andersen, M.D., who has led the Company since 2012. Dr. Andersen will retain his role as Chief Operating Officer and serve until Septe... 
Printer Friendly Version
02/09/17Forward Pharma Received US$ 1.25bn pursuant to Settlement and License Agreement with Biogen
COPENHAGEN, Denmark, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward”) today announced that it has received a non-refundable cash fee of US$ 1.25 billion in connection with the execution and delivery of a Settlement and License Agreement with two wholly owned subsidiaries of Biogen Inc. and certain other parties (the “License Agreement”). On January 17, 2017 Forward entered into the License Agreement subject to the approval of its shareholders and certain... 
Printer Friendly Version
02/01/17Forward Pharma Announces Results of Extraordinary General Meeting
Forward obtains shareholder approval for Settlement and License Agreement with Biogen COPENHAGEN, Denmark, Feb. 01, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward”) today announced that, at an extraordinary general meeting of its shareholders held on February 1, 2017 (the “Extraordinary General Meeting”), the requisite two-thirds majority of the votes cast as well as the share capital represented at the Extraordinary General Meeting approved the entry into a Settle... 
Printer Friendly Version
01/17/17Forward Pharma Agrees to Enter Into Settlement and License Agreement with Biogen
Biogen will pay Forward a non-refundable cash fee of $1.25 billion Forward may be eligible to receive royalties of 10% of net sales of Tecfidera beginning in 2021, and of 20% of net sales beginning in 2029, depending on the outcome of certain existing litigation and the receipt of regulatory approvals COPENHAGEN, Denmark, Jan. 17, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward”) today announced that it has entered into a binding agreement with two wholly owne... 
Printer Friendly Version
Upcoming EventsMore >>
Forward Pharma A/S at Deutsche Bank 42nd Annual Health Care Conference
Forward Pharma A/S at Jefferies 2017 Global Healthcare Conference
LocationNew York, NY
Forward Pharma A/S at JMP Securities Life Sciences Conference
LocationNew York, NY
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Forward Pharma A/S posts new information to the site. Just enter your e-mail address and click Submit.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources